The diagnostic value of high-resolution CT combined with serum TUBA1B and ACSL4 in differentiating benign and malignant solitary pulmonary nodules
10.13491/j.issn.1004-714X.2026.03.012
- VernacularTitle:高分辨率CT联合血清TUBA1B、ACSL4对孤立性肺结节良恶性的鉴别诊断价值
- Author:
Bin LI
1
;
Jiming LIU
1
;
Mingjun WU
2
Author Information
1. Department of Medical Imaging, Baoji People’s Hospital, Baoji 721000, China.
2. Department of Thoracic Surgery, Baoji People’s Hospital, Baoji 721000, China.
- Publication Type:OriginalArticles
- Keywords:
Solitary pulmonary nodule;
High-resolution CT;
Tubulin alpha-1B;
Long-chain acyl-CoA synthetase 4
- From:
Chinese Journal of Radiological Health
2026;35(3):387-393
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of combining high-resolution CT (HRCT) with serum markers in differentiating malignant solitary pulmonary nodules (SPN). Methods Ninety-two SPN patients admitted to Baoji People’s Hospital between January 2022 and January 2024 were included. According to pathological analysis, they were divided into a benign group (30 cases) and a malignant group (62 cases). The serum levels of TUBA1B and ACSL4 were detected. Diagnostic value was determined using the receiver operating characteristic curve. Kappa test was used for consistency evaluation. Results Significant differences were observed between the benign and malignant groups in HRCT imaging, including the number of cases with spiculation, lobulation, pleural indentation, calcification, and vascular convergence sign (P<0.05). The sensitivity, specificity, and accuracy of HRCT in diagnosing malignant SPN were 74.19%, 86.67%, and 78.26%, respectively. The consistency with clinical diagnosis was moderate, as indicated by a Kappa value of 0.552 (P<0.001). The expression level of TUBA1B in the serum of SPN patients in the malignant group was higher than that in the benign group (P<0.05), while the expression level of ACSL4 was lower than that in the benign group (P<0.05). The areas under the receiver operating characteristic curves of serum TUBA1B and ACSL4 in diagnosing malignant SPN were 0.840 (95%CI = 0.749-0.908) and 0.875 (95%CI = 0.790-0.935), respectively, with sensitivities of 74.19% and 75.81% and specificities of 73.33% and 86.67%, respectively. The sensitivity, specificity, and accuracy of HRCT combined with serum TUBA1B and ACSL4 in diagnosing malignant SPN were 96.77%, 63.33%, and 85.87%, respectively. The consistency with clinical diagnosis was high, as indicated by a Kappa value of 0.721 (P<0.001). The sensitivity and negative predictive value of HRCT combined with serum TUBA1B and ACSL4 in diagnosing malignant SPN were higher than those of individual diagnostic indicators (P<0.05). Conclusion HRCT combined with serum TUBA1B and ACSL4 has high value in the differentiation of benign and malignant SPN.
